Bishnoi R, et al. - Among diabetic patients diagnosed with colorectal (CRC) and lung cancers, researchers assessed how overall survival (OS) was influenced by treatment with dipeptidyl peptidase 4 (DPP4) inhibitors in this Surveillance Epidemiology and Endpoint Research-Medicare database study. According to the findings, improved OS was reported in relation to DPP4 inhibition in CRC and lung cancer. The impact of DPP4 inhibition on immunoregulation of cancer was suggested to be the possible reason behind this survival benefit. An even more pronounced survival advantage was seen when DPP4 inhibitors were used in combination of metformin, which is known to suppress cancer.